Dear FDA Commissioner Andrew von Eschenbach:
These comments to Docket No. FDA-2008-N-0416 are in response to the Food and Drug Administration’s (FDA) August 7, 2008 notice of public meeting and request for comments. The meeting was organized, and the comments and data requested, to assist the agency in further implementing the recommendations of the 2006 Nanotechnology Task Force report on what the agency should do about FDA-regulated products that may contain nanoscale materials. We appreciate this opportunity to provide comments to the FDA on this important and pressing issue.